Related Experiment Video

Updated: Jun 10, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

[Concurrent chemoradiotherapy for localized nasal NK/T-cell lymphoma]

Motoko Yamaguchi

    [Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
    |August 10, 2010
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Translationally-Relevant Tumor Resection Model for Murine Preclinical Models of Oral Squamous Cell Carcinoma
    07:59

    Translationally-Relevant Tumor Resection Model for Murine Preclinical Models of Oral Squamous Cell Carcinoma

    Published on: April 3, 2026

    Related Experiment Videos

    Last Updated: Jun 10, 2026

    Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
    07:29

    Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

    Published on: April 22, 2019

    Translationally-Relevant Tumor Resection Model for Murine Preclinical Models of Oral Squamous Cell Carcinoma
    07:59

    Translationally-Relevant Tumor Resection Model for Murine Preclinical Models of Oral Squamous Cell Carcinoma

    Published on: April 3, 2026

    Related Concept Videos

    Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

    Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

    Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
    Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

    Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

    5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

    Articles linked to this work by shared authors, journal, and citation graph.

    [Recent advances and future perspectives in the treatment of NK/T-cell lymphoma].

    [Rinsho ketsueki] The Japanese journal of clinical hematology·2026

    Synchronous diffuse large B-cell lymphoma and gynecological malignancy treated with paclitaxel and carboplatin: A report of two cases.

    Journal of clinical and experimental hematopathology : JCEH·2026

    [Mentorship to support career development among women physicians].

    [Rinsho ketsueki] The Japanese journal of clinical hematology·2026

    Treatment and outcomes of pulmonary mucosa-associated lymphoid tissue lymphoma: A multicenter analysis of 186 patients.

    Cancer·2026

    Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.

    Leukemia·2026

    Protocol digest of a randomized phase III study of pola-R-CHP/high-dose methotrexate/IT vs. pola-R-CHP/IT for newly diagnosed diffuse large B-cell lymphoma with high risk of central nervous system relapse: JCOG2201 (PREMIER).

    Japanese journal of clinical oncology·2025

    [Clinical management of familial platelet disorder with associated myeloid malignancies: at the crossroads of hematology and clinical genetics].

    [Rinsho ketsueki] The Japanese journal of clinical hematology·2026

    [DDX41-mutated myeloid neoplasms].

    [Rinsho ketsueki] The Japanese journal of clinical hematology·2026

    [Clinical significance of germline pathogenic variants associated with hematologic malignancies].

    [Rinsho ketsueki] The Japanese journal of clinical hematology·2026

    [Future directions in clinical development of first-line therapy for diffuse large B-cell lymphoma].

    [Rinsho ketsueki] The Japanese journal of clinical hematology·2026

    [Novel therapeutic strategies to separate GVHD from GVL based on GVHD pathophysiology and mechanisms of leukemia relapse].

    [Rinsho ketsueki] The Japanese journal of clinical hematology·2026

    [New developments in cord blood transplantation: immunological characteristics and strategies for relapse prevention].

    [Rinsho ketsueki] The Japanese journal of clinical hematology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us